4th Quarter - Report

INTRA-CELLULAR THERAPIES, INC. for INTRA-CELLULAR THERAPIES, INC.

Firm
Client
Income
—
Expenses
$40,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

P.L. 117-169: Legislation not yet introduced; Negotiation regarding IRA Maximum Fair Price (MFP) and small manufacturer exception. H.R. 7174: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program - Provisions regarding reforms to the Inflation Reduction Act (IRA) MFP negotiation process.

LobbyistCovered position, as disclosed
ANDREW SPERLING —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: H.R. 7174 (118th)

Health Issues HCR

S. 1339: Pharmacy Benefit Manager Reform Act - Provisions regarding regulation of pharmacy benefit managers. S. 2973: Modernizing and Ensuring PBM Accountability Act - Provisions regarding regulation of pharmacy benefit managers.

LobbyistCovered position, as disclosed
ANDREW SPERLING —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 2973 (118th), S. 1339 (118th)

Taxation/Internal Revenue Code TAX

HR 3938: Build it in America Act - Provisions regarding research and development tax credit amortization. S. 866: American Innovation and Jobs Act - Provisions regarding research and development tax credit amortization.

LobbyistCovered position, as disclosed
ANDREW SPERLING —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 866 (118th), H.R. 3938 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.